The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin…
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on…
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety…
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI PlatformBOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI…
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…
BRECKENRIDGE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and a…
NEW YORK and LONDON and SAO PAOLO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed…
Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after…
Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on…